Legend:
CC = Vancouver Convention Centre
F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
|
|
|
632 !
|
Thu, 8/2/2018,
8:30 AM -
10:20 AM
|
CC-West 115
|
|
Statistical Issues Specific the Therapeutic Areas-4 — Contributed Papers
|
|
Biopharmaceutical Section
|
|
Chair(s): Wen-Chi Wu, Merck
|
|
8:35 AM
|
Variational Inference for Proportional Hazards Model with Power Prior in Oncology Studies
Bo Jin, Boston Biomedical Inc.; Yue Chang, Boston Biomedical Inc
|
|
8:50 AM
|
Utilization of Historical Data and Real World Evidence in Clinical Trial Development - Case Studies in Rare Disease and Oncology
Florence H Yong, Pfizer Inc.; Ray Li, Pfizer Inc.; Steven Y Hua, Celgene - Receptos; Jeffery Palmer, Pfizer Inc.; Roberto Bugarini, Pfizer Inc.
|
|
9:05 AM
|
Mathematical Modeling Identifies Optimum Lapatinib Dosing Schedules for the Treatment of Glioblastoma Patients
Shayna Stein, Harvard University; Franziska Michor, Dana Farber Cancer Institute
|
|
9:20 AM
|
Evaluation of Statistical Methods for Survival Analysis with Time-Dependent Variables
Chris Holland, Amgen; Qui Tran, Amgen; Cassie Dong, Amgen
|
|
9:35 AM
|
Predicting the Long-Term Exposure in Acute Treatment of Migraine Using a Nonhomogeneous Poisson Process with Random Effects
Kaifeng Lu
|
|
9:50 AM
|
Statistical Challenges and Opportunities in Drug Development for Rare Diseases
Guowen Sun, BioMarin; Keith Gregg, BioMarin; Peter Slasor, BioMarin; Chito Hernandez, BioMarin Pharmaceutical Inc.
|
|
10:05 AM
|
Optimal Treatment Recommendation via Subgroup Identification in Randomized Control Trials
Yang (Grace) Zhao, Gilead Sciences; Haoda Fu, Eli Lilly and Company
|
